On 7 July, Annovis Bio, a clinical-stage drug platform company developing novel treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson’s disease (PD), announced that is has received Central Institutional Review Board (IRB) approval to initiate a new Phase II clinical study investigating its lead compound ANVS401 in AD and PD. ANVS401 is a small orally administrated brain penetrant inhibitor of neurotoxic proteins. The purpose of the IRB is to assure that appropriate steps are taken to protect the rights and welfare of participants in a research study. The company is expecting to enrol 68 research participants with early AD and early PD at 15 sites across the US. They will receive ANVS401 for one month.
